Oncogenic Wnt3a expression as an estimable prognostic marker for hepatocellular carcinoma

Table 1 Clinical characteristics of hepatocellular carcinoma patients

Parameter	n
Age (yr)
median (range)	51 (35-74)
Gender
Male	62
Female	18
Differentiation
Poor	34
Moderate	41
Well	5
Tumor number
Single	64
Multiple	16
Liver cirrhosis
Absent	29
Present	51
HBV infection
Absent	15
Present	65
Periportal embolus
Absent	9
Present	71
AFP (ng/mL)
< 400	52
≥ 400	28
TNM staging
I-II	36
III-IV	44
Five-year survival
Yes	32
No	48

HBV: Hepatitis B virus; AFP: α-fetoprotein; TNM: Tumor-node-metastasis.

Table 2 Incidence of liver Wnt3a expression and its scores with staining strength in cancerous and surrounding tissues

Group	n	Wnt3a		χ2	P value	Wnt3a strength				Z value	P value
		Neg.	Pos.			0	1-2	3-4	5-6
HCC	80	3	77	48.818	< 0.0011	3	20	34	23	8.274	< 0.0011
Para-can	80	43	37			41	28	11	0

¹Compared with the para-cancerous group. HCC: Hepatocellular carcinoma; Para-can: Para-cancerous tissues; Neg.: Negative Wnt3a expression; Pos.: Positive Wnt3a expression.

Table 3 Clinicopathological characteristics of high Wnt3a expression in 80 hepatocellular carcinoma patients

Groups	Patients, n	% of total	Wnt3a high expression, n	% of total	χ2	P value
Differentiation					20.211	< 0.001
Poor	34	42.50	31	91.18
Moderate	41	51.25	26	63.41
Well	5	6.25	0	0.00
Tumor number					0.976	0.323
Single	64	80.00	44	68.75
Multiple	16	20.00	13	81.25
Liver cirrhosis					8.467	0.004
Absent	29	36.25	15	51.72
Present	51	63.75	42	82.35
HBV infection					12.957	< 0.001
Absent	15	18.75	5	33.33
Present	65	81.25	52	80.00
Periportal embolus					3.557	0.059
Absent	9	11.25	4	44.44
Present	71	88.75	53	74.65
AFP (ng/mL)					1.020	0.313
< 400	52	65.00	39	75.00
≥ 400	28	35.00	18	64.28
TNM staging					22.960	< 0.001
I-II	36	45.00	16	44.44
III-IV	44	55.00	41	93.18
Five-year survival					15.469	< 0.001
Yes	32	40.00	15	46.88
No	48	60.00	42	87.50

HBV: Hepatitis B virus; AFP: α-fetoprotein; TNM: Tumor-node-metastasis.

Table 4 Univariate and multivariable analysis of prognostic factors in hepatocellular carcinoma for 5-year survival

Variable	Univariate analysis			Multivariable analysis
	HR	P >|z|	95%CI	HR	P > |z|	95%CI
Age (yr)
≤ 60 vs > 60	0.828	0.662	0.355-1.930
Gender
Male vs female	1.005	0.990	0.440-2.296
Differentiation
Low vs high	1.037	0.914	0.539-1.993
Tumor number
Single vs multiple	0.867	0.720	0.397-1.893
Liver cirrhosis
Absent vs present	2.101	0.035	1.053-4.195	2.021	0.033	1.057-3.864
HBV infection
Absent vs present	0.327	0.029	0.120-0.892	0.325	0.010	0.138-0.765
Periportal embolus
Absent vs present	0.499	0.360	0.113-2.210
AFP (ng/mL)
< 400 vs≥ 400	0.938	0.725	0.655-1.342
TNM staging
I-II vs III-IV	0.686	0.318	0.328-1.436
Wnt3a expression
Low vs high	5.656	< 0.001	2.682-11.926	3.651	< 0.001	1.973-6.757

HBV: Hepatitis B virus; AFP: α-fetoprotein; TNM: Tumor-node-metastasis.